FlexShares Ultra-Short Income Fund (ARCA: RAVI)

Latest news for FlexShares Ultra-Short Income Fund (ARCA:RAVI)

FlexShares Ultra-Short Income Fund

FlexShares Ready Access Variable Income Fund

The fund seeks to achieve its investment objective by investing at least 80% of its total assets in a non-diversified portfolio of fixed-income instruments, including bonds, debt securities and other similar instruments issued by U.S. and non-U.S. public and private sector entities. The dollar-weighted average portfolio maturity of the fund is normally not expected to exceed two years. It may invest up to 20% of its total assets in fixed-income securities and instruments of issuers in emerging markets. The fund is non-diversified.

FlexShares Ultra Short Income Fund

RAVIO ENTMT CORP UNSP/ADR by Ravio Entmt Corp.

BMO Capital analyst Fadi Chamoun maintains C.H. Robinson Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRW#NASDAQ">CHRW</a>) with a Market Perform and raises the price target from $85 to $92.

News

Price Target

Analyst Ratings

CHRW

BMO Capital Maintains Market Perform on C.H. Robinson Worldwide, Raises Price Target to $92

Barclays analyst Andrew Mok maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Equal-Weight and lowers the price target from $370 to $364.

Barclays Maintains Equal-Weight on Humana, Lowers Price Target to $364

A British billionaire who made a fortune while working for a top commodities company was charged with corruption on Thursday. The company previously <a href="https://www.benzinga.com/government/22/05/27390214/commodity-trader-glencore-looks-to-settle-bribery-market-manipulation-charges-by-paying-penalties-up">pleaded guilty to corruption in 2022</a>.
What Happened: Alex Beard, a billionaire and former head of oil at Glencore ADR (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GLNCY#OTC">GLNCY</a>), has been charged with corruption by the UK&#8217;s Serious Fraud Office (SFO), alongside four other former Glencore employees, <a href="https://www.bloomberg.com/news/articles/2024-08-01/glencore-s-billionaire-ex-oil-head-alex-beard-charged-with-corruption-by-uk?sref=TBDibEcD">per</a> Bloomberg. Beard served as head of oil at Glencore for over a decade before leaving in 2019.
Beard is accused of conspiring to make corrupt payments to benefit Glencore's oil operations in West Africa. The SFO accused Beard of improper actions with government officials and employees of state-owned oil firms in Nigeria and Cameroon between 2007 and 2014.
Beard's former deputy, Andy Gibson also faces allegations of making corrupt payments in Nigeria, Cameroon and the Ivory Coast, and falsifying invoices. Additional charges were brought against Paul Hopkirk, Ramon Labiaga and Martin Wakefield, former Glencore employees involved in West African oil trading. All four former Glencore employees are set to appear in a British court on Sept. 10.
Glencore, founded in 1974 by the late Marc Rich, is a commodity giant with mines, oil, trading, and agriculture operations worldwide. The company — which went public in 2011 — has a market cap of 49.55 billion pounds ($63,273,863,500).
This follows Glencore&#8217;s 2022 guilty plea to corruption and market manipulation in the U.S. and U.K., resulting in $1.5 billion in fines. Beard, who founded Adaptogen Capital post-Glencore, exited his role there on July 12.
"Bribery damages financial markets and causes lasting harm to communities," SFO Director Nick Ephgrave <a href="https://www.ft.com/content/27b66a9f-b1e6-4c49-83a7-f7896539ad2e?FTCamp=engage/CAPI/desktopapp/Channel_Bloomberg//B2B">told</a> the Financial Times in a statement. "Today's action is an important step towards exposing overseas corruption and holding those who are responsible to account."&nbsp;
Beard has a net worth of $2 billion <a href="https://www.forbes.com/profile/alex-beard/">according</a> to Forbes. Beard owned 2.5% of Glencore in 2019. He was born in London and attended Oxford University.
Price Action: Glencore shares were trading at $10.69, down 3.26% at the time of writing.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/07/39976031/visa-leverages-ai-to-prevent-40b-in-fraud-how-machine-learning-is-combatting-the-surge-in-cyberc">Visa Leverages AI To Prevent $40B In Fraud: How Machine Learning Is Combatting The Surge In Cybercrime And AI-Driven Scams</a></li>
</ul>
Photo: Einstock via Shutterstock

Equities

Commodities

Legal

Global

GLNCY

Mining Billionaire Charged With Corruption In British Court: What You Need To Know

As the presidential election looms, many Americans are weighing how their vote might impact their financial future. Should investors be concerned about how <a href="https://www.benzinga.com/markets/equities/24/07/39726239/trump-win-in-november-will-boost-the-stock-market-says-goldman-sachs-but-not-all-sectors-will-be">election outcomes might influence the stock market</a>? Conventional wisdom might suggest that the occupant of the Oval Office wields influence over market performance, as presidential policies can reshape industries, alter trade relationships, and impact consumer spending. 
Don't Miss:
<ul>
<li>This billion-dollar fund has invested in the next big real estate boom,<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> here's how you can join for $10.</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends<a href="https://www.benzinga.com/money/arrived-private-credit-fund"> would you invest in it</a>?</li>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
</ul>
 But a deeper dive into historical data reveals a more nuanced picture, according to Ryan Detrick, chief market strategist at the Carson Group.
Detrick&#8217;s analysis of decades of stock market performance under various administrations reveals a pattern, he told CNBC Make It. Had an investor put $1,000 into the broad U.S. stock market in 1953 and only kept it invested during Republican presidencies, they&#8217;d have just under $30,000 today. The same strategy, but only investing under Democrats, would yield about $60,000. However, staying invested throughout that entire period, regardless of who occupied the Oval Office, would have resulted in $1.7 million.
See Also: Don&#8217;t miss the real AI boom &#8211;<a href="https://www.benzinga.com/money/fundrise-innovation-fund"> here&#8217;s how to use just $10 to invest in high growth private tech companies.</a>
&#8220;A lot of people didn&#8217;t like President Obama. A lot of people didn&#8217;t like President Donald Trump. A lot of people don&#8217;t like President Biden. The stock market did just fine under all three of them,&#8221; Detrick told CNBC.
That long-term perspective points to something important: the market tends to trend upward over time, <a href="https://www.benzinga.com/markets/24/07/40048127/the-truth-behind-market-returns-during-election-years-and-presidential-terms">regardless of which party controls the White House</a>. In fact, the broad U.S. stock market has seen gains in 17 out of the 20 four-year administrations since Eisenhower took office, the CNBC report noted.
But if partisan control does matter, where should investors look? Interestingly, gridlock in Washington might be a bullish signal. &#8220;What&#8217;s going to matter more [than the Presidential election] is the makeup of Congress,&#8221; Detrick notes. &#8220;When you have a divided Congress, that tends to be the best thing.&#8221;\
<hr class="wp-block-separator has-alpha-channel-opacity" />
Trending: America's construction sites are desperate for Robots —<a href="https://www.benzinga.com/money/apis-cor"> here&#8217;s how to invest in a house-printing startup who&#8217;s making them and be a part of a $16 trillion industry</a>.
<hr class="wp-block-separator has-alpha-channel-opacity" />
Experts, including Detrick, caution against making investment decisions based solely on political outcomes. Nick Murray, a financial advisor, reported election-related anxiety among investors before the 2020 election. In his newsletter, Murray advised, &#8220;Take your political convictions completely out of your investment decision making … There is zero basis, in fact, for this conviction.&#8221;
The 2016 election serves as a reminder of what happens when trying to predict market reactions to political events. As Donald Trump&#8217;s unexpected victory became clear on election night, futures plummeted. Yet by the market close the following day, the S&amp;P 500 had risen more than 1%, defying predictions, Murray noted.
While historical trends can provide context—like increased market volatility in the months before elections—they don&#8217;t predict future performance. Ultimately, Detrick said broader economic factors matter more than political outcomes. &#8220;The bottom line is that politics are fun to watch. They matter, and they should matter to people. But when it comes to your investments, how the economy is doing is what matters,&#8221; he said to CNBC.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/irs-finalizes-10-year-rule-adv">IRS Finalizes 10-Year Rule For Retirement Withdrawals, Making Things &#8216;Even More Insanely Complicated&#8217;</a></li>
<li>Warren Buffett flipped his neighbor's $67,000 life savings into a $50 million fortune —<a href="https://www.benzinga.com/money/advisor-adv-warren-buffett"> How much is that worth today? </a></li>
</ul>

Startups

Do Stocks Care About Who The President Is Like We Do? Here's What The Data Says

Piper Sandler analyst Andrew Liesch maintains Central Pacific Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPF#NYSE">CPF</a>) with a Overweight and raises the price target from $24 to $30.

Piper Sandler Maintains Overweight on Central Pacific Financial, Raises Price Target to $30

APA's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APA#NYSE">APA</a>) short percent of float has fallen 27.35% since its last report. The company recently reported that it has 16.55 million shares sold short, which is 5.1% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.66 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>APA Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722528931_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for APA has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing APA's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, APA's peer group average for short interest as a percentage of float is 6.28%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Peering Into APA's Recent Short Interest

Windtree Therapeutics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NYSE">WINT</a>) short percent of float has fallen 17.46% since its last report. The company recently reported that it has 47 thousand shares sold short, which is 7.99% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.22 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Windtree Therapeutics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722528921_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Windtree Therapeutics has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Windtree Therapeutics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Windtree Therapeutics's peer group average for short interest as a percentage of float is 6.71%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

WINT

(WINT) - Analyzing Windtree Therapeutics's Short Interest

Zoom Video Comms's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NYSE">ZM</a>) short percent of float has fallen 3.14% since its last report. The company recently reported that it has 8.91 million shares sold short, which is 3.39% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.21 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Zoom Video Comms Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722528911_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Zoom Video Comms has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Zoom Video Comms's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Zoom Video Comms's peer group average for short interest as a percentage of float is 3.35%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Zoom Video Comms's Recent Short Interest

Piper Sandler analyst Clarke Jeffries maintains AvidXchange Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDX#NASDAQ">AVDX</a>) with a Neutral and lowers the price target from $12 to $9.

AVDX

Piper Sandler Maintains Neutral on AvidXchange Holdings, Lowers Price Target to $9

BioNTech SE &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) shares are trading lower by 5.67% to $81.32 during Thursday&#8217;s session. Shares of various vaccine manufacturers are declining after Moderna Inc <a href="https://www.benzinga.com/pressreleases/24/08/ac40094041/moderna-reports-second-quarter-2024-financial-results-and-provides-business-updates">adjusted its 2024 outlook due</a> to weak EU sales, indicated possible revenue deferrals for some international sales into 2025 and noted an &#8216;increasingly competitive environment&#8217; for respiratory vaccines in the U.S.
<h2 class="wp-block-heading">Why This Matters To BNTX Investors</h2>
BioNTech is a key player in the mRNA vaccine market, particularly known for its COVID-19 vaccine developed in partnership with Pfizer Inc. Moderna&#8217;s announcement of low EU sales could signal broader market trends affecting mRNA vaccines, implying that BioNTech might also face similar challenges in the European market, where demand could be lower than anticipated.
Additionally, Moderna&#8217;s mention of potential revenue deferrals for international sales into 2025 suggests that global vaccination campaigns might be slowing down or facing logistical issues. This could affect BioNTech&#8217;s international sales and revenue projections, creating investor concerns about the company&#8217;s short-term financial performance and cash flow.
Read More: <a href="https://www.benzinga.com/news/24/08/40101256/why-ocugen-ocgn-stock-is-falling">Why Ocugen (OCGN) Stock Is Falling</a>
Moreover, the increasingly competitive environment for respiratory vaccines in the U.S. could be a significant factor. As competition intensifies, BioNTech may face pressure on its market share, pricing power, and profit margins. This competitive landscape includes not only Moderna but also other companies like Novavax and traditional pharmaceutical giants that are entering or expanding their presence in the respiratory vaccine market. 
Investors might worry that BioNTech will need to increase spending on marketing, research and development to maintain its competitive edge, which could impact its profitability.
<h2 class="wp-block-heading">How To Buy BNTX Stock</h2>
By now you're likely curious about how to participate in the market for BioNTech &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stocks, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
In the the case of BioNTech, which is trading at $86.2 as of publishing time, $100 would buy you 1.16 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, BNTX has a 52-week high of $125.83 and a 52-week low of $78.02.

BNTX

What's Going On With BioNTech (BNTX) Shares?

Barclays analyst George Wang maintains Garmin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRMN#NYSE">GRMN</a>) with a Equal-Weight and raises the price target from $166 to $181.

GRMN

Barclays Maintains Equal-Weight on Garmin, Raises Price Target to $181

Piper Sandler analyst Frank Schiraldi maintains Northfield Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFBK#NASDAQ">NFBK</a>) with a Neutral and raises the price target from $11 to $13.

NFBK

Piper Sandler Maintains Neutral on Northfield Bancorp, Raises Price Target to $13

WIIM

TransAlta shares are trading higher after the company reported better-than-expected Q2 financial results and reaffirmed its FY24 guidance.

The Dow Jones index closed higher by around 99 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Augusta Gold</h3>
<ul>
<li>The Trade: Augusta Gold Corp (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AUGG#OTC">AUGG</a>) Executive Chairman Richard W Warke <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 15,000 shares </a>at an average price of $0.56. To acquire these shares, it cost around $8,400.</li>
<li>What's Happening: On June 28, Augusta Gold announced a loan extension.</li>
<li>What Augusta Gold Does: Augusta Gold Corp is an exploration-stage company. The company is primarily engaged in the acquisition and exploration of gold properties. It operates Bullfrog Project, located in Beatty town of Las Vegas, Nevada.</li>
</ul>
<h3 class="wp-block-heading">Stemtech</h3>
<ul>
<li>The Trade: Stemtech Corporation (OTC:<a class="ticker" href="https://www.benzinga.com/stock/STEK#OTC">STEK</a>) Director Charles Stuart Arnold <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 25,000 shares at</a> an average price of $0.05. To acquire these shares, it cost around $1,250.</li>
<li>What's Happening: On April 2, Stemtech announced Darryl V. Green to Direct Company Rebranding Project.</li>
<li>What Stemtech Does: Stemtech Corp is a nutraceutical company. Its products enhance and support the work of the body&#8217;s stem cells by releasing more stem cells, helping to circulate them in the blood and migrate them into tissues, where perform their daily function of renewal for optimal health.</li>
</ul>
<h3 class="wp-block-heading">Pineapple Financial</h3>
<ul>
<li>The Trade: Pineapple Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAPL#NYSE">PAPL</a>) COO Kendall Leo Marin <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 4,000 shares</a> at an average price of $1.01. The insider spent around $4,029 to buy those shares.</li>
<li>What's Happening: On July 16, Pineapple Financial posted downbeat quarterly results.</li>
<li>What Pineapple Financial Does: Pineapple Financial Inc is a Canada-based mortgage technology and brokerage company that provides mortgage brokerage services and technology solutions to Canadian mortgage agents, brokers, sub-brokers, brokerages, and consumers.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40101200/top-3-health-care-stocks-that-are-set-to-fly-this-quarter">Top 3 Health Care Stocks That Are Set To Fly This Quarter</a></li>
</ul>

Long Ideas

Penny Stocks

Markets

AUGG

PAPL

STEK

Pineapple Financial And 2 Other Penny Stocks Insiders Are Buying

Shares of Qualcomm Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) were falling on Thursday, despite the company reporting <a href="https://www.benzinga.com/markets/equities/24/07/40065100/whats-going-on-with-starbucks-stock-wednesday">upbeat fiscal third-quarter results</a>.
The results came amid an <a href="https://www.benzinga.com/earnings">exciting earnings season</a>. Here are some key analyst takeaways.
Piper Sandler On Qualcomm
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58fe05b80bd9910001595370/harsh-kumar">Analyst Harsh Kumar</a> reiterated an Overweight rating, while raising the price target from $185 to $205.
Qualcomm reported its quarterly results and guidance ahead of expectations for both revenues and earnings, with the outperformance being driven by "strength coming from Android as well as the upcoming ramp with QCOM&#8217;s modem only customer," Kumar said in a note. The extra week in the September quarter will offset the earlier-than-expected revoking of the company's license to sell to Huawei, he added.
Although Qualcomm reported strong growth in its automotive business, "the segment was guided flat sequentially for September," the analyst stated. The company continued to "cite opportunities around the AI PC which are encouraging in our view," he further wrote.
JPMorgan On Qualcomm
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58ac4af2b85e930001e6383f/samik-chatterjee">Analyst Samik Chatterjee</a> maintained an Overweight rating, while cutting the price target from $235 to $230.
Qualcomm delivered an earnings beat on stronger revenues of $9.4 billion versus consensus of $9.2 billion, Chatterjee said. Earnings came in at $2.33, higher than Street expectations of $2.26, he added.
"The strength of the premium smartphone market in relation to Chinese OEMs as well as upsides in the Autos and IoT businesses, which are critical to Qualcomm's efforts towards diversification of its end-markets, helped deliver results for F3Q that exceeded investor expectations," the analyst wrote. The company's fiscal fourth-quarter guidance was also better than feared, despite concerns around headwinds from the end of the license to ship to Huawei, he further stated.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Cantor Fitzgerald On Qualcomm
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/6331beac10b15f0001b58380/c-j%20muse">Analyst C.J. Muse</a> reaffirmed a Neutral rating and price target of $215.
While June results and September guide came ahead of expectations, the company's initial guidance for the December quarter reflects only 5% year-on-year growth, which was "disappointing," Muse said. Management was preparing investors for "removing Huawei out of model," he added.
"The major takeaway was diversification and uplift to both the June and September Qs from Automotive," the analyst wrote. He added that auto revenues grew 34% sequentially to $811 million, "a clear indication the company is well on its way to achieving its stated goal of $4B in revenues by FY26 and $9B by FY31," he further stated.
WestPark Capital On Qualcomm
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/617bd9cab650db0001533a25/kevin-garrigan">Analyst Kevin Garrigan</a> reiterated a Hold rating on the stock.
"The company benefited from strength in the premium-tier smartphone market, as well as upside in both Automotive and IoT segments," Garrigan wrote in a note. The fiscal fourth-quarter guidance benefits from an extra week but includes the headwind of export restrictions to Huawei, he added.
"Management noted the Huawei headwind would persist into Q1 FY25," the analyst wrote. Revenue generation from AI "is likely to be more of a FY25 story, in our view," he further stated.
Oppenheimer On Qualcomm
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58b6cbc3b85e9300014425be/rick-schafer">Analyst Rick Schafer</a> maintained a Perform rating on the stock.
Qualcomm's results were mixed, Schafer said. He added that Apple Inc "remains motivated to part with QCOM, a lingering $10B overhang."
While reports suggest Apple's modem could debut in some iPhone 17 SKUs launching next year, Android is expected to be "seasonally lower in F4Q," the analyst stated. "It remains to be seen whether AI will drive a meaningful acceleration in refresh and/or demonstrably grow TAM," he further wrote.
QCOM Price Action: Shares of Qualcomm were down 8.7% to $165.57 at the time of publication on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40104359/amazons-bullish-trend-powers-up-can-q2-earnings-fuel-a-breakout">Amazon&#8217;s Bullish Trend Powers Up: Can Q2 Earnings Fuel A Breakout?</a></li>
</ul>
Photo: Shutterstock

AAPL

QCOM

Qualcomm Exceeds Expectations In Q3: 5 Analysts Debate Impact Of Huawei Export Restrictions

Piper Sandler analyst Yasmeen Rahimi maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Overweight and lowers the price target from $70 to $52.

SAGE

Piper Sandler Maintains Overweight on Sage Therapeutics, Lowers Price Target to $52

Boeing shares are trading lower after the company on Wednesday reported worse-than-expected Q2 results and appointed Kelly Ortberg as new CEO. The stock gained following the report and is lower on Thursday.

Barclays analyst Duffy Fischer maintains DuPont de Nemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) with a Equal-Weight and raises the price target from $85 to $88.

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

FlexShares Ultra-Short Income Fund

News

Latest news for FlexShares Ultra-Short Income Fund (ARCA:RAVI)

Tuesday, September 08, 2015